{
  "slug": "nmn",
  "name": "NMN (β-Nicotinamide Mononucleotide)",
  "alternate_names": [
    "β-NMN",
    "Nicotinamide Mononucleotide"
  ],
  "mechanism": [
    "NAD+ salvage pathway substrate",
    "Sirtuin family co-substrate",
    "Mitochondrial biogenesis"
  ],
  "target": [
    "NAD+ pool",
    "Sirtuins (SIRT1-7)",
    "CD38",
    "Mitochondria"
  ],
  "use_case": [
    "healthy aging",
    "metabolic surrogate",
    "athletic recovery",
    "NAD+ decline"
  ],
  "body_system": [
    "MITO",
    "METABOLISM",
    "CNS",
    "IMMUNE"
  ],
  "evidence_tier": "A",
  "evidence_anchor_pmid_count": 56,
  "evidence_long_form_url": "https://asxan.ai/blog/nmn-vs-nr-decision-tree-evidence/",
  "dosage_range": "250-1000 mg/day (functional benefit RCTs at 250 mg/day · safety to 1250 mg/day for 4 weeks)",
  "safety_notes": "No adequate human data in pregnancy/lactation/ART · TGA permissible upper 500 mg/day · long-term safety beyond 12 months not established",
  "regulatory": {
    "fda": "NDI pending (2022 NDIN ruling withdrawn 2023 · marketed as dietary supplement under existing DSHEA)",
    "efsa": "Novel Food classification (no authorized claim)",
    "anvisa": "RDC 243/2018 dietary supplement framework · IN 28/2018 alegações funcionais not authorized"
  },
  "ingredient_hub_url": "https://asxan.ai/ingredients/nmn/",
  "related_goal_slugs": [
    "longevity-stack",
    "athletic-performance",
    "cognitive-support",
    "heart-health"
  ],
  "related_lifestyle_slugs": [
    "senior-60-plus",
    "high-stress",
    "intermittent-fasting"
  ],
  "last_evidence_review": "2026-05-26",
  "schema_version": "nc-public-v0.1"
}